ERCC1 polymorphisms and oxaliplatin. A review of the literature and a monocentric experience in the absence of a ‘sliding doors’ trial

Publication date: Available online 28 January 2017
Source:Critical Reviews in Oncology/Hematology
Author(s): V. Formica, E. Doldo, F.R. Antonetti, A. Nardecchia, P. Ferroni, S. Riondino, C. Morelli, H.T. Arkenau, F. Guadagni, A. Orlandi, M. Roselli
Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. Germline ERCC1 polymorphisms may alter the protein expression and published data on their predictive and prognostic value have so far been contradictory. In the present article we review available evidence on the clinical role and utility of ERCC1 polymorphisms and, in the absence of a 'perfect' trial, what we call the 'sliding doors' trial, we present the data of ERCC1 genotyping in our local patient population finding a useful predictive value for oxaliplatin-induced risk of anemia.



http://ift.tt/2kFwHBC